Intech Investment Management LLC Takes Position in Humacyte, Inc. (NASDAQ:HUMA)

Intech Investment Management LLC bought a new position in shares of Humacyte, Inc. (NASDAQ:HUMA) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 42,615 shares of the company’s stock, valued at approximately $232,000.

A number of other hedge funds have also made changes to their positions in the company. Renaissance Technologies LLC raised its stake in shares of Humacyte by 693.0% in the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after acquiring an additional 524,600 shares during the last quarter. Vanguard Group Inc. increased its holdings in Humacyte by 28.7% during the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after purchasing an additional 896,415 shares in the last quarter. Thrivent Financial for Lutherans bought a new position in Humacyte in the 3rd quarter valued at $712,000. Millennium Management LLC boosted its stake in Humacyte by 504.3% in the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after purchasing an additional 1,334,641 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Humacyte by 62.7% during the second quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company’s stock worth $1,219,000 after purchasing an additional 97,931 shares during the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Price Performance

Shares of HUMA opened at $4.49 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61. Humacyte, Inc. has a twelve month low of $2.48 and a twelve month high of $9.97. The stock has a market capitalization of $565.11 million, a P/E ratio of -3.35 and a beta of 1.38. The company has a 50 day moving average of $5.13 and a 200-day moving average of $6.10.

Wall Street Analysts Forecast Growth

HUMA has been the subject of several research reports. EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. BTIG Research reissued a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. TD Cowen reiterated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Benchmark reissued a “buy” rating and set a $15.00 price objective on shares of Humacyte in a report on Thursday, October 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 price target on shares of Humacyte in a research report on Friday, September 20th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Humacyte currently has an average rating of “Buy” and a consensus price target of $13.00.

Insider Activity at Humacyte

In other news, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the sale, the director now directly owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Laura E. Niklason sold 157,704 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $5.42, for a total value of $854,755.68. Following the completion of the sale, the chief executive officer now directly owns 3,519,558 shares of the company’s stock, valued at approximately $19,076,004.36. The trade was a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,662,886 shares of company stock valued at $7,489,538. 11.20% of the stock is owned by insiders.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.